News About: Pharm. Industry
Will Yuhan and Gilead cooperate for the hepatitis C drug, ‘Sovaldi’?The alliance of Gilead and Yuhan Corporation, which has shown the perfect match in the hepatitis B market, has attracted attention for possibility to keep the trend in the hepat...
|
Pros and cons of Dong-A ST’s Baraclude generic early launchDespite existence of the substance patent, Dong-A ST launched a Baraclude generic on the 7th, giving various explanations in the industry. The explanations are divided into two ...
|
Joint marketing between BMS and Green Cross for ‘Baraclude’
BMS Korea(President Hye-sun Park) will jointly sell ‘Baraclude,’ a chronic hepatitis B treatment, with Green Cross(President Eun-cheol Huh) in the domestic market. On the 11th, the two companies announced establishmen...
Reason why domestic companies need to get involved in special biopharmaceutical distribution
Multinational distribution companies and international expression couriers, such as DHL Express, FedEx Healthcare Shipping Solutions and World Courier Clinical Trial Logistics, have aggressively been getting involved ...
Dong-A breaking through the patent wall of BaracludeLast July, Dong-A ST has rapidly launched ‘Baracle Tab,’ a generic of Baraclude which left a month to its patent expiration. Its strategy is to preoccupy the market by breaking ...
|
Pfizer’s labor and management oppose over ERPWhen it comes to the Pfizer Korea’s ERP(Early Retirement Program), its labor union and management have run parallel.
On the last 7th, the labor union started a tent sit-in stri...
|
‘Lively’ OTC market from a series of product launches
A series of OTC drug launches have been made in the pharmaceutical industry. The OTC market has finally been active.
First, movements of Daewon Pharm, which entered the OTC market in 10 years, have attracted attentio...
Austin Pharmaceutical announced for sale with open competitive bidding methodAustin Pharmaceutical, an unlisted company, attracted interests of the industry as entering the sale market.
Austin Pharmaceutical is a new name of Walse Korea Pharmaceutical, ...
|
The sunset period for tax deduction of pharmaceutical companies will be reviewed to extend
A taxation support plan to nurture the pharmaceutical industry is about to be reviewed.
On the 8th, the Korea Health Industry Development Institute announced invitation of bidding for the ‘Taxation Support Plan Studi...
Samsung Bioepis acquired domestic approval for Brenzys™Samsung Bioepis and MSD Korea announced the Samsung Bioepis’s first biosimilar, Brenzys™, has been approved by the Ministry of Food and Drug Safety(MFDS) on the 7th.
The MFDS a...
|
